Shots:

• Imcyse to receive up front- ~$180M as milestones along with royalties. Pfizer to purchase an equity stake in Imcyse
• Initially- the companies will collaborate to develop existing lead candidates and further optimize potential molecules. Later- Pfizer will lead clinical development and commercialization activities for the program
• The Imotope platform is a curative approach to severe autoimmune diseases. Imcyse plan to initiate a P-II study with its lead candidate in T1D and MS in 2022

 ­ Ref: Accesswire | Image: Imcyse